ARIAD Pharmaceuticals, Inc.
ARIAD Announces Preliminary Results from Ongoing Clinical Trial of Its Investigational, Bcr-Abl Inhibitor – AP24534 – in Drug-Resistant Chronic Myeloid Leukemia
Published in Cancer Weekly, August 11th, 2009
ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) announced preliminary clinical data from an ongoing Phase 1 clinical trial of its investigational, multi-targeted kinase inhibitor, AP24534, in patients with advanced hematological cancers. The study results provide initial clinical evidence of hematologic, cytogenetic and molecular anti-cancer activity of AP24534 in heavily pretreated patients with resistant and refractory chronic myeloid leukemia (CML), including those with the T315I mutant variant of the target protein, Bcr-Abl. An abstract describing these data is being submitted for presentation at a major hematology meeting to be held later this year.
Treatment of CML or...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2009-08-11)
More Articles from Cancer Weekly
- American Cancer Society
Study finds acceptable levels of anxiety among men living with early, untreated prostate cancer - Ludwig Institute for Cancer Research
Could therapeutic vaccines treat hard to beat breast cancers? - University of Maryland Medical Center
Low prevalence of HPV infection may be tied to poor prognosis for blacks with head and neck cancer - Angiogenesis
PTC Therapeutics Initiates Phase 2 Clinical Trial of PTC299 in Patients with Neurofibromatosis Type 2 - AuthorHouse
'Stepping Over Myself': From Promising Tennis Player to Death's Door - Cancer Gene Therapy
New cancer gene therapy study findings have been published by scientists at Northeastern University - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
